Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD

762.63

+24.29 (3.29%)

At close: Jul 31, 2026, 4:00 PM EDT

761.45

-1.18 (-0.16%)

After-hours: Jul 31, 2026, 7:49 PM EDT

Regeneron Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2,456	3,118	2,488	2,730	3,106	2,886
Short-Term Investments	5,539	5,487	6,524	8,115	4,636	2,809
Cash & Short-Term Investments	7,995	8,605	9,013	10,845	7,742	5,695
Cash Growth	7.03%	-4.52%	-16.90%	40.07%	35.96%	58.76%
Accounts Receivable	6,565	5,741	6,212	5,667	5,329	6,037
Inventory	3,084	3,201	3,087	2,581	2,402	1,951
Other Current Assets	801.7	474.8	349.2	386.6	411.2	332.4
Total Current Assets	18,446	18,022	18,661	19,479	15,884	14,015
Net Property, Plant & Equipment	5,459	5,120	4,600	4,146	3,763	3,482
Other Intangible Assets	1,310	1,257	1,149	1,039	915.5	6.7
Long-Term Investments	9,828	10,261	8,900	5,397	6,592	6,838
Other Long-Term Assets	6,688	5,898	4,450	3,020	2,060	1,093
Total Assets	41,731	40,559	37,759	33,080	29,215	25,435

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	1,159	939	789.5	606.6	589.2	564
Accrued Expenses	2,967	2,876	2,527	2,358	2,074	2,207
Current Portion of Leases	720	-	-	-	-	719.7
Unearned Revenue	684.8	553	627.7	458.9	477.9	442
Total Current Liabilities	5,531	4,368	3,944	3,423	3,141	3,933
Long-Term Debt	1,987	1,986	1,984	1,983	1,981	1,980
Long-Term Leases	-	720	720	720	720	-
Other Long-Term Liabilities	2,502	2,228	1,757	980.8	707.8	753.5
Total Long-Term Liabilities	4,489	4,933	4,462	3,684	3,409	2,734
Total Liabilities	10,019	9,302	8,406	7,107	6,551	6,666

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.1	0.1	0.1	0.1	0.1	0.1
Treasury Stock	-20,575	-18,613	-15,167	-12,560	-10,353	-8,261
Additional Paid-in Capital	14,701	13,995	12,856	11,354	9,949	8,088
Accumulated Other Comprehensive Income	-35.8	77.5	-7.9	-80.9	-238.8	-26.2
Retained Earnings	37,621	35,797	31,673	27,260	23,307	18,968
Shareholders' Equity	31,711	31,257	29,354	25,973	22,664	18,769
Total Liabilities & Equity	41,731	40,559	37,759	33,080	29,215	25,435

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2,707	2,706	2,704	2,703	2,701	2,700
Net Cash (Debt)	5,288	5,899	6,308	8,142	5,041	2,995
Net Cash Growth	10.99%	-6.48%	-22.52%	61.52%	68.31%	236.03%
Net Cash Per Share	49.37	54.32	54.80	71.61	44.41	26.69
Book Value	31,711	31,257	29,354	25,973	22,664	18,769
Book Value Per Share	296.09	287.82	255.03	228.44	199.68	167.28
Tangible Book Value	30,402	30,000	28,205	24,935	21,749	18,762
Tangible Book Value Per Share	283.86	276.24	245.05	219.30	191.62	167.22

SEC Filings: 10-K · 10-Q